

HEMATOPATHOLOGY REQUISITION FORM

THIS SECTION FOR PHENOPATH USE ONLY

HEME

CLINICAL SPECIMEN INFORMATION

Hosp/Inst where specimen collected _____
Collection Date _____ Collection Time _____
Specimen ID _____ Block #/Sublabel _____ Tissue Source(s) _____

- Paraffin blocks: Tissue block(s) _____ Cell block(s) _____
 Formalin Bouin's B5 Prefer Michel's (skin IF TM) Other
 Slides: Unstained _____ Stained _____
 Smears: Air-dried _____ Fixed _____ Stained _____
 Blood BM aspirate BM core bx Body Fluid/CSF
 CBC/WBC DIFFERENTIAL RESULTS (REQUIRED) - please attach

NOTE: Flow Cytometry: Heparin preferred, EDTA ok
Fresh Specimens for PCR or FISH: EDTA preferred, Heparin ok

Multiple specimens submitted: Test all Select best block

DIAGNOSIS BEING CONSIDERED / REQUEST

- R/O non Hodgkin lymphoma R/O myeloid neoplasm
 R/O Hodgkin lymphoma R/O any hematolymphoid neoplasm
 R/O plasma cell neoplasm R/O acute leukemia

PATIENT HISTORY

- See letter Report Included Report not available

- Full bone marrow evaluation (Flow cytometry, morphology, cytogenetics)
 Diagnostic / IHC Consultations
 With molecular studies determined medically necessary by PhenoPath MDs

FLOW CYTOMETRY (diagnosis under consideration)

- B cell lymphoma/mature LPD T cell Lymphoma/mature LPD Both B & T cell
 B cell Acute lymphoblastic leukemia (ALL)
 T cell Acute lymphoblastic leukemia (ALL)
 Plasma cell dyscrasia AML CML/MPD MDS PNH
 MRD testing for _____
 Other _____

FISH PANELS * Available on paraffin embedded tissue blocks and/or slides only

Panel	Individual Test
<input type="checkbox"/> ALL Panel	<input type="checkbox"/> t(9;22)BCR/ABL <input type="checkbox"/> 11q23 MLL <input type="checkbox"/> ETV6/RUNX1 <input type="checkbox"/> MYC (8q24) <input type="checkbox"/> CDKN2A/CEP9*
<input type="checkbox"/> AML Panel	<input type="checkbox"/> t(8;21) <input type="checkbox"/> t(15;17) <input type="checkbox"/> Inv16 (CBFB) <input type="checkbox"/> 7q31/del 7q <input type="checkbox"/> EGR1 <input type="checkbox"/> 11q23 MLL <input type="checkbox"/> CEP8
<input type="checkbox"/> APL Panel	<input type="checkbox"/> t(15;17) PML/RARA <input type="checkbox"/> RARA Breakapart
<input type="checkbox"/> CLL/SLL Panel	<input type="checkbox"/> 11q22.3 ATM <input type="checkbox"/> 13q14_D13S25 <input type="checkbox"/> 17p13.1_P53 <input type="checkbox"/> CEP12 <input type="checkbox"/> IGH <input type="checkbox"/> t(11;14)CCND1/IGH
<input type="checkbox"/> CML Panel	<input type="checkbox"/> t(9;22) BCR/ABL
<input type="checkbox"/> MALT Panel	<input type="checkbox"/> MALT (18q21)* <input type="checkbox"/> If (+) reflex to: t(11;18) MALT/AP12 & t(14;18) IGH/MALT
<input type="checkbox"/> MDS Panel	<input type="checkbox"/> ERG1 <input type="checkbox"/> 7q31/del7q <input type="checkbox"/> CEP8 <input type="checkbox"/> 20q12 See web or molecular req for non-heme FISH
<input type="checkbox"/> MYC Panel	<input type="checkbox"/> MYC(8q24) <input type="checkbox"/> IGH
<input type="checkbox"/> NHL: Aggressive B-NHL Panel	<input type="checkbox"/> MYC(8q24) <input type="checkbox"/> IGH <input type="checkbox"/> t(14;18) IGH/BCL-2 <input type="checkbox"/> BCL6
<input type="checkbox"/> NHL: Indolent B-NHL Panel	<input type="checkbox"/> t(14;18) IGH/BCL-2 <input type="checkbox"/> IGH <input type="checkbox"/> BCL6 <input type="checkbox"/> t(11;14)CCND1/IGH <input type="checkbox"/> MALT1 (18q21)*
<input type="checkbox"/> Myeloma Panel	<input type="checkbox"/> 1q21+1p21 <input type="checkbox"/> 13q14_D13S25 <input type="checkbox"/> 17p13.1_P53 <input type="checkbox"/> t(11;14)CCND1/IGH <input type="checkbox"/> t(14;16) IGH/MAF <input type="checkbox"/> t(4;14) FGFR3/IGH <input type="checkbox"/> CEP3, 5, 7, 9, 11, 15 (Panel makeup subject to change)
<input type="checkbox"/> MPN Panel	<input type="checkbox"/> 13q14_D13S25 <input type="checkbox"/> 20q12 <input type="checkbox"/> CEP8 <input type="checkbox"/> CEP9

PCR See web or molecular req for detailed PCR tests

- B cell (IgH) only MYD88 L265P BRAF V600 (hairly cell leukemia)
 B cell (IgK Kappa) only IgVH mutation analysis (prognosis in CLL/SLL and HCL)*
 B cell IgH & IgK Kappa BCR-ABL Major (p210) only JAK2 V617F
 B cell (IgH) w/reflex to IgK (Kappa) if (-) BCR-ABL Minor (p190) only JAK2 Exon 12*
 T cell (TCR-γ) only Both Major & Minor Calreticulin Exon 9
 T cell (TCR-β) only BCR-ABL1 w/reflex to JAK2 MPL (W515)*
 T cell TCR-γ & TCR-β JAK2 V617F w/reflex to CALR if (-) If JAK2 V617F (-) and CALR (-), reflex to MPL*
 T cell (TCR-γ) w/reflex to (TCR-β) if (-)

*Testing is not performed at PhenoPath and will be forwarded to an outside facility

CYTOGENETICS / FISH

- Chromosome analysis / karyotyping Reflexive FISH analysis (if needed)

Send: REQS: Heme Molecular General Derm Stain Only

REQUESTING INSTITUTION NAME & ADDRESS

Material and report will be returned to the address provided below:

Phone _____ FAX _____

Ordering Pathologist/Physician

Name _____ NPI # _____

Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.

PATIENT INFORMATION

Name (Last, First, MI) _____

SSN # _____ DOB _____ Male Female

- Inpatient Outpatient Non-Hospital Patient

Address _____ Phone _____

Medical Record # _____ Pt # _____

TREATING PHYSICIAN

Name _____ NPI # _____

Mail/Fax add'l copy of report to treating physician
Information REQUIRED, if not complete report will **NOT** be faxed/mailed

Phone _____ Fax _____

Institution _____

Address _____

City, State Zip _____

BILLING INFO (Complete and accurate information must be provided, including billing instructions, or Client will be billed)

BILL: Insurance* Medicare Medicaid (WA DSHS only)

Requesting Institution† Patient

PO# _____ ICD-10 # _____

Referral/Authorization # _____

*If 3rd party billing is requested, a copy of the face sheet and front/back of patient's insurance/Medicare card MUST be attached

†If bill requesting institution has been selected, ENTIRE billing address MUST be included

Institution _____

Address _____

City, State Zip _____

CONTACT INFO

Person completing form _____

Date _____ Phone _____

PhenoBoxes Flow Media IF Media Date Needed By: _____

By submitting a specimen with this requisition form, you agree:

- 1) The information provided on this form and accompanying paperwork is complete and accurate.
- 2) If the information is not accurate, and PhenoPath cannot obtain reimbursement for services that have been requested and provided, Client agrees to accept financial responsibility.
- 3) If a service does not have an established Medicare allowable, PhenoPath will bill the Client.
- 4) Requests for testing PhenoPath does NOT perform (for current test menu, consult PhenoPath's website – www.phenopath.com or contact Client Services at 206.374.9000, or Toll-free at 888.92.PHENO (888.927.4366):
 - a) PhenoPath may forward specimens to an alternate facility for testing it does not perform, upon authorization by Client.
 - b) PhenoPath will manage return of applicable specimen to Client.
 - c) By signing the authorization form, Client agrees to pay for authorized services that are not paid for by a third party. PhenoPath can only bill for professional services provided by PhenoPath.

ICD-10 – All providers, laboratories, institutions, hospitals and other providers ordering laboratory testing to be performed by PhenoPath Laboratories must provide ICD-10-CM diagnosis codes for all testing submitted for dates of service October 1, 2015 and greater.

Links: <https://www.cms.gov/Medicare/Coding/ICD10/index.html?redirect=/ICD10> and <http://www.cdc.gov/nchs/icd/icd10cm.htm#icd2014>

Direct Bill Law – Washington is a “direct-bill” state for anatomic pathology services (RCW 48.43.081, <http://apps.leg.wa.gov/rcw/default.aspx?cite=48.43.081>). This means that PhenoPath can only send a bill to the entity who ordered the services (or to the patient or their insurance). We cannot bill a 3rd party.

MEDICARE COVERAGE DETERMINATIONS – PhenoPath is a Medicare participating provider, and is subject to the local coverage determinations (LCD) of the Medicare Administrative Contractor (MAC) for Jurisdiction F, Noridian Healthcare Solutions, Contractor No. 02402. Additional information can be obtained online at: <https://www.noridianmedicare.com/partb/coverage/active.html>.

SELECTED LOCAL COVERAGE DETERMINATIONS (LCD)

LCD Title	LCD ID No.	Original Effective Date
Cytogenetic Studies	L24295	12/01/2006
Flow Cytometry	L35208	06/16/2015
Genetic Testing	L24308	12/01/2006
Genetic Testing for BCR-ABL Negative Myeloproliferative Disease	L36186	04/19/2016
MolDx: Breast Cancer Genetic Assay	L35500	06/22/2015
Non-Covered Services	L24473	11/01/2007
Special Histochemical Stains and Immunohistochemical Stains	L36353	10/15/2015

MEDICARE MEDICAL NECESSITY REQUIREMENTS – When ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements may apply:

- 1) Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered. Medicare does not pay for screening tests, except for certain specifically approved procedures, and may not pay for non-FDA-approved tests or tests considered experimental.
- 2) If there is reason to believe that Medicare will not pay for a test, the patient should be informed, and asked to sign an Advance Beneficiary Notice (ABN) to indicate whether he/she accepts responsibility for the cost of the test if Medicare denies payment.
- 3) Diagnosis information is requested from ordering physicians in order to support the medical necessity of each test ordered. ICD-10 codes are required on the test requisition for dates of service October 1, 2015 and greater (ICD-9 codes are required for dates of service prior to October 1, 2015). Narrative descriptions may be acceptable. PhenoPath will contact Client to obtain diagnosis information for reasons including, but not limited to the following:
 - A diagnosis code or narrative description is not provided.
 - The provided diagnosis narrative description appears inconsistent with the patient's demographic, the patient's medical condition, or the testing services being ordered.
 - The provided diagnosis or narrative description does not meet the coverage criteria as supporting medical necessity for testing services covered by a Medicare LCD.
- 4) Organ- or disease-oriented panels should be billed to Medicare only when every component of the panel is medically necessary. The OIG takes the position that a physician who orders medically unnecessary tests for which Medicare reimbursement is claimed may be subject to civil penalties. PhenoPath- and client-customized panels should be billed to Medicare only when every component of the customized panel is medically necessary. PhenoPath offers groups of tests based on accepted clinical practice.

Advanced Beneficiary Notice (“ABN”) – An ABN, Form CMS-R-131, is a standardized notice you must issue to a Medicare beneficiary before providing certain Medicare Part B (outpatient) or Part A (limited to hospice, home health agencies [HHAs], and Religious Nonmedical Healthcare Institutions only) items or services. You must issue the ABN when:

- You believe Medicare may not pay for an item or service;
- Medicare usually covers the item or service; and
- Medicare may not consider the item or service medically reasonable and necessary for this patient in this particular instance. You should only provide ABNs to beneficiaries enrolled in original (fee-for-service) Medicare. ABNs allow beneficiaries to make informed decisions about whether to get services and accept financial responsibility for those services if Medicare does not pay. The ABN serves as proof the beneficiary knew prior to getting the service that Medicare might not pay. If you do not issue a valid ABN to the beneficiary when Medicare requires it, you cannot bill the beneficiary for the service, and you may be financially liable if Medicare doesn't pay. You may also use the ABN as an optional (voluntary) notice to alert beneficiaries of their financial liability prior to providing care that Medicare never covers. ABN issuance is not required to bill a beneficiary for an item or service that is not a Medicare benefit and never covered.
- If you order a test that does not meet Medicare's medical necessity guidelines, it is important that you complete an ABN and have it signed by the patient at the time of service. This will allow you and PhenoPath to bill the patient for the services provided if Medicare does not reimburse us for the test(s) and if the patient has accepted the financial responsibility. Medicare defines medical necessity as services that are: reasonable and necessary, for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member, and not excluded under another provision of the Medicare Program. All services reported to the Medicare Program by health care professionals must demonstrate medical necessity through the use of International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnostic coding carried to the highest level of specificity for the date of service.
- If the testing does not meet Medicare medical necessity guidelines, the patient does not sign an ABN, and Medicare fails to reimburse for the test(s) ordered, PhenoPath may bill the referring lab/physician for the services provided.

PhenoPath's billing practices have been developed to ensure compliance with federally mandated rules. Direct questions about invoices to our Medical Billing department at 1-866-927-4366 or 206-374-1480. Fax inquiries to 206-774-3412. The department is generally staffed Monday to Friday from 6 am to 4:30 pm Pacific time.